BeiGene
BGNE
#981
Rank
$19.61 B
Marketcap
$175.87
Share price
-1.78%
Change (1 day)
-3.61%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -$0.88 Billion USD

According to BeiGene 's latest financial reports the company's current earnings are $3.31 Billion USD. In 2023 the company made an earning of -$1.21 Billion USD, an increase over its 2022 earnings that were of -$1.79 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

201620192022- $1.5B- $1B- $0.5B$0.5B0companiesmarketcap.com

Annual earnings

Year Earnings Change
2024 (TTM) -$0.88 Billion-27.75%
2023 -$1.21 Billion-32.52%
2022 -$1.79 Billion24.39%
2021 -$1.44 Billion-13.21%
2020 -$1.66 Billion72.69%
2019 -$0.96 Billion36.01%
2018 -$0.71 Billion616.83%
2017 -$98.46 Million-15.24%
2016 -$0.12 Billion107.91%
2015 -$55.88 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-$18.16 Million-97.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.12 Billion-86.49%๐Ÿ‡บ๐Ÿ‡ธ USA